Beijing Lepu Pharmaceutical Technology Co., Ltd.

Main purpose: To study Lepu in healthy subjects under fasting or postprandial conditions, using Sildenafil Citrate Tablets (trade name: Viagra®; Specification: 100mg) held by Pfizer Pharmaceuticals Co., Ltd. as a reference preparation. The absorption speed and extent of sildenafil citrate tablets (specification: 100mg) developed by Pharmaceutical Co., Ltd. were evaluated to evaluate whether the test preparation and the reference preparation are bioequivalent. Secondary purpose: To observe the safety of oral administration of the test preparation and reference preparation to healthy subjects.

Main purpose: In healthy subjects, under fasting and postprandial conditions, Boehringer Ingelheim Pharmaceuticals, Inc held Empagliflozin Metformin Sustained Release Tablets (trade name: SYNJARDY® XR; specification: Empagliflozin 5 mg/metformin hydrochloride 1000 mg) was used as the reference preparation to study the pharmacokinetics of empagliflozin metformin sustained-release tablets (specification: empagliflozin 5 mg/metformin hydrochloride 1000 mg) developed by Lepu Pharmaceutical Co., Ltd. , to evaluate whether the test preparation is bioequivalent to the reference preparation. Secondary purpose: To observe the safety of oral test preparation and reference preparation in healthy subjects.

Main purpose: Under fasting and postprandial conditions, healthy subjects were treated with sacubitril valsartan sodium tablets held by Novartis Pharma Schweiz AG (trade name: Nuoxintuo®; specification: 100 mg, sacubitril 49 mg/valsartan 51 mg) was used as the reference preparation, and sacubitril valsartan sodium tablets (specification: 100 mg, sacubitril 49 mg/valsartan 51 mg) developed by Lepu Pharmaceutical Co., Ltd. mg) pharmacokinetics to evaluate the bioequivalence between the test preparation and the reference preparation. Secondary purpose: To observe the safety of oral test preparation and reference preparation in healthy subjects.